Please ensure Javascript is enabled for purposes of website accessibility
Contactez-nous Contactez-nous
FR
Accueil > Products > Anticorps > Anticorps Primaires

Anti-Obinutuzumab Polyclonal Antibody (AY257014)

Fiche technique Partager le produit Copier les informations
Prix(USD) :
Spécification :
  • 50ug
  • 100ug
  • 1mg
Nombre :
Contactez-nous

  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueAY257014
Description
Anti-Obinutuzumab Polyclonal Antibody (AY257014) is a rabbit polyclonal antibody detecting Obinutuzumab in ELISA.
Highlights
  • ●Affinity Purified — Minimal background and high purity for reliable results.
Reactivité des espècesGeneral
ApplicationsELISA
Espèce hôteRabbit
ClonalitéPolyclonal
IsotypeIgG
Immunogène Obinutuzumab
Cible Rabbit polyclonal to Gazyva.
Spécificité The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Niveau d'endotoxines Please contact with the lab for this information.
Pureté >90% as determined by SDS-PAGE.
Purification Purified by antigen affinity column.
Numéro d'accès CAS: 949142-50-1
Forme Liquid
Tampon de stockage 0.01M PBS pH 7.4

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Informations d'utilisation du produit
Application Dilution
ELISA 1:5000-1:20000
IHC 1:50-1:500
WB 1:500-1:2000
Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
ContexteObinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Note For research use only.
Images
Reférences
Fiche technique
Download SDS PDF
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs

Obtenir un devis gratuit
Anti-Obinutuzumab Polyclonal Antibody

Accès rapide

Contactez-nous

  • +86-027-65523339

  • [email protected]

  • Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine

  • linkedin
  • Ins
  • youtube
  • youtube
Droit d'auteur © 2026 abinScience. Tous droits réservés. Tous les produits sont uniquement à usage de recherche